EHC
NVCR icon

Everett Harris & Co’s NovoCure NVCR Stock Holding History

Everett Harris & Co’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$232K – 272
2021
Q3 		$232K Hold
2,000
– – ﹤0.01% 244
2021
Q2 		$444K Hold
2,000
– – 0.01% 189
2021
Q1 		$264K Hold
2,000
– – ﹤0.01% 229
2020
Q4 		$346K Hold
2,000
– – 0.01% 208
2020
Q3 		$223K Buy
+2,000
New +$160K ﹤0.01% 228

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everett Harris & Co's NVCR Position: Q4 2021 in Review

Everett Harris & Co sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,000 shares — an estimated $232K sold.

Everett Harris & Co first reported a position in NVCR in Q3 2020 and held it in 5 quarters. The position peaked at $444K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Everett Harris & Co reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Everett Harris & Co sold 2,000 NovoCure shares in Q4 2021, an estimated $232K.
  • Everett Harris & Co first reported a position in NovoCure in Q3 2020 and held it in 5 quarters.
  • Everett Harris & Co's NovoCure position peaked at $444K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Everett Harris & Co's 13F filing for Q4 2021, filed 2 Feb 2022.